NC-based clinical-stage biotech company, Doron Therapeutics has secured $11M in Series A Funding led by SPRIM Global Investments (SGI) to take MOTYS™ into Phase 3 clinical studies.
Read also – Sirona Medical Secures $42 Mn Series C Financing
Doron’s advanced product, MOTYS™, is an intra-articular biologic drug to manage symptomatic knee osteoarthritis. The Osteoarthritis Research Society International (OARSI) World Congress 2024 in Vienna, Austria featured a podium presentation of data from a Phase 2 clinical trial. MOTYS™ was identified as an up-and-coming program to address the significant impact of debilitating osteoarthritis.
Read also – Constrafor Raises $264M Investment for Construction’s Future
MOTYS™ is being developed to provide potent and durable effects from a single injection, with compelling preclinical evidence of superiority compared to currently available therapies, including steroids and hyaluronic acid. The product has a robust CMC package and clinical data from over 350 patients.
“We are excited for Doron to join our portfolio of companies – and see a great opportunity for their program to be successful and disrupt the vast and growing global market of osteoarthritis,” said Michael Shleifer, managing partner of SPRIM.
“We are grateful to our Series A investors, for their confidence in our initiative,” said Alessandra Pavesio, chief executive officer and co-founder of Doron. “This is an exciting time for Doron as we progress our lead product into Phase 3 clinical studies. The unmet need for non-surgical interventions in osteoarthritis is immense and growing. We believe MOTYS™ will allow patients to have reduced pain and regain function, allowing them the opportunity to get back to healthy and active lives.”
About Doron Therapeutics
Doron Therapeutics is a clinical-stage biotechnology company that has developed a Phase 3 ready, intra-articular biologic drug derived from placental tissue. The lead product, MOTYS™, consistently delivers a host of beneficial growth factors with potent anti-inflammatory, tissue-protective and regenerative capabilities pivotal to the progressive and degenerative disease of osteoarthritis.
